CTLA4 and nonpapillary renal cell carcinoma: The clinical success of immune checkpoint inhibitors (ICIs) that target programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) have revolutionized the treatment of ccRCC patients.